 |
Prospector
Profile
07.1283
|
| |
| Opko Health, Inc. |
NAICS |
541710 |
| 4400 Biscayne Boulevard, Suite 1180
Miami, FL 33137 |
Description |
Biotechnology |
| (305) 575-6015 |
Employees |
17 |
| http://www.opko.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-0.8860 |
| |
Assets |
(mil) |
8.7520 |
| |
Liability |
(mil) |
0.6740 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
OPKO Health, Inc. reported a net loss of $11.1 million for the three months ended June 30, 2007, a huge increase over the $0.3 million net loss reported during the same period last year. For the six months ended June 30, 2007, the Company reported a net loss of $261 million, a large jump from the $0.3 million net loss reported during the first half of 2006. The large net loss reported during the first half of 2007 is primarily due to a $243.8 million write-off of acquired in- process research and development. The Company's balance sheet reflected an accumulated deficit of $261.9 million as of June 30, 2007.
|
| |
|
Intellectual Property:
Historically, the Company obtains protection, where possible, on its intellectual property and other proprietary rights, including protection of its products, processes and technologies. The Company licenses such processes and technologies to generate royalties but has not received any revenues under any of its licensing agreements during the past three years. [SEC Filing 10-K 03-22-07]
|
| |
|
Description:
The Company develops therapies for the treatment and prevention of ophthalmic disorders and diseases.
|
| |
|
Officers:
John A. Paganelli (Chair, Interim CEO & Sec.); Dr. David F. Hostelley (CFO)
|
| |
|
Auditor:
BDO Seidman LLP
|
| |
|
Securities:
Common Stock-Symbol OPK; AMEX;
161,020,191 common shares outstanding as of August 6, 2007.
|
| |
| |
| |
| return to main page |
|
|
